Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.

particularly as the UK has a relatively high incidence of CF, and the second largest disease population in the world. It is two and a half years since Vertex’s Orkambi (lumacaftor+ivacaftor ...

Britain is likely to be blasted by a polar vertex as a huge snow bomb covers several parts of the country in two weeks' time, weather maps have suggested. However, around 24 counties in the UK may not ...

This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 ...

Vertex and CRISPR reckon there are around 2,000 patients in the UK eligible for Casgevy. “Both sickle cell disease and beta thalassemia are painful, life-long conditions that in some cases can ...

Vertex added it has also completed regulatory submissions for the vanzacaftor triple therapy in the EU, UK, and Canada, among ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...